{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-003110","form_type":"8-K","ticker":"CHRS","cik":"0001512762","company_name":"Coherus Oncology, Inc.","filed_at":"2024-03-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.436098+00:00","generated_at":"2026-06-04T22:12:49.526142+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Coherus reports FY2023 revenue $257.2M, divests CIMERLI to Sandoz for $170M, plans debt paydown","bullets":["Q4 2023 net revenue $91.5M (+102% YoY); FY2023 $257.2M (+22% YoY); net loss $79.7M Q4, $237.9M FY.","Closed ophthalmology divestiture to Sandoz on March 1 for $170M upfront plus $17.8M inventory/assets.","Plans to prepay $175M of $250M term loan by April 1, cutting interest ~70%; workforce reduction of 30%.","Launched LOQTORZI (NPC) and UDENYCA ONBODY in Q1 2024; UDENYCA market share 26% as of March 1.","2024 guidance: SG&A+R&D $250-265M (down from $301.5M in 2023); annual cost savings >$25M."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-003110","json":"https://secwatch.observer/filing/0001558370-24-003110.json","markdown":"https://secwatch.observer/filing/0001558370-24-003110.md","text":"https://secwatch.observer/filing/0001558370-24-003110.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024003110/0001558370-24-003110-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024003110/chrs-20240313x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T22:12:49.526142+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"abe324305126376e6ddb3cd78d50e987f2add3aa","claim":"Coherus Oncology, Inc. reported financial results for fiscal year ended December 31, 2023.","evidence_excerpt":"On March 13, 2024, Coherus BioSciences, Inc. (the “Company”) issued a press release regarding its financial results for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1512762/000155837024003110/0001558370-24-003110-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}